Instead, intramuscular injections may be more suitable
Molecular assembly of an aptamerdrug conjugate for targeted drug delivery to tumor cells
Additional resources FAQ IGF-1 LR3 is a modified form of IGF-1, it is more potent and stable than unmodified IGF-1

Food and Drug Administration (FDA) European Medicines Agency (EMA) Centers for Disease Control and Prevention (CDC) National Institutes of Health (NIH) United Nations Population Division Global Health Data Exchange Trade Publications Pharmaceutical Technology Diabetes Care Endocrinology Today The Pharmaceutical Journal Medical News Today Academic Journals The Lancet Diabetes & Endocrinology Journal of Clinical Endocrinology & Metabolism Diabetes Research and Clinical Practice Nature Reviews Endocrinology Journal of Diabetes Science and Technology Diabetes, Obesity and Metabolism Reputable Newspapers The New York Times The Guardian Financial Times Wall Street Journal The Washington Post Industry Associations American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) International Diabetes Federation (IDF) Diabetes UK American Association of Clinical Endocrinologists (AACE) Public Domain Resources National Library of Medicine (NLM) U.S

It provides a highly effective, clinically viable alternative that bypasses hepatic first-pass metabolism, specifically designed to maximize adherence
Two are FDA-approved specifically as injectable weight loss medications: Saxenda (liraglutide) approved in 2014, injected once daily